Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Tecfidera
Tecfidera
Biogen chalks up a Tecfidera patent win in Europe after losing US protections
Biogen chalks up a Tecfidera patent win in Europe after losing US protections
Fierce Pharma
Biogen
Tecfidera
multiple sclerosis
Europe
Flag link:
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Seeking Alpha
Biogen
EMA
Europe
MS
multiple sclerosis
Tecfidera
generics
Flag link:
Biogen gains prominent ally in bid for Supreme Court to review Tecfidera patent case
Biogen gains prominent ally in bid for Supreme Court to review Tecfidera patent case
Fierce Pharma
Biogen
Tecfidera
patents
Supreme Court
Flag link:
Split U.S. appeals court rejects Biogen bid to revive MS drug patent dispute
Split U.S. appeals court rejects Biogen bid to revive MS drug patent dispute
Reuters
Biogen
Mylan
Tecfidera
patents
multiple sclerosis
MS
Flag link:
Biogen takes another blow as appeal for Tecfidera patent revival falls short
Biogen takes another blow as appeal for Tecfidera patent revival falls short
Fierce Pharma
Biogen
Tecfidera
patents
multiple sclerosis
MS
Flag link:
Biogen is running out of safety nets
Biogen is running out of safety nets
BioPharma Dive
Biogen
Vumerity
Tecfidera
Spinraza
aducanumab
Flag link:
Mylan launches first generic to Tecfidera in multiple sclerosis
Mylan launches first generic to Tecfidera in multiple sclerosis
Seeking Alpha
Mylan
generics
Tecfidera
Biogen
MS
multiple sclerosis
Flag link:
Biogen's last-ditch pitch for an injunction to protect Tecfidera is denied, paving way for Mylan generic
Biogen's last-ditch pitch for an injunction to protect Tecfidera is denied, paving way for Mylan generic
Endpoints
Biogen
Tecfidera
Mylan
generics
Flag link:
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Fierce Pharma
Biogen
Tecfidera
Mylan
patents
generics
MS
multiple sclerosis
Flag link:
Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan
Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan
Fierce Pharma
Biogen
Mylan
Tecfidera
patents
MS
multiple sclerosis
Flag link:
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Motley Fool
Biogen
Mylan
Alzheimer's disease
patents
Tecfidera
MS
multiple sclerosis
Vumerity
Flag link:
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up
Fierce Pharma
Biogen
patents
Tecfidera
Mylan
multiple sclerosis
MS
Flag link:
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Motley Fool
Biogen
MS
multiple sclerois
Alzheimer's disease
Tecfidera
aducanumab
Flag link:
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Multiple Sclerosis News Today
Biogen
MS
multiple sclerosis
Vumerity
drug pricing
Tecfidera
Flag link:
A new company enters the Tecfidera fight, offering to kill two birds
A new company enters the Tecfidera fight, offering to kill two birds
Endpoints
Biogen
Tecfidera
MS
flushing
Vitalis Pharmaceuticals
Flag link:
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Fierce Pharma
Biogen
Tecfidera
MS
multiple sclerosis
Flag link:
Biogen beats estimates on multiple sclerosis therapy sales Reuters
Biogen beats estimates on multiple sclerosis therapy sales Reuters
Yahoo/Reuters
Biogen
earnings
Tecfidera
Flag link:
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Flag link:
Upcoming events – key tests approach for Biogen and Kalvista
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Flag link:
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
EP Vantage
Biogen
Alzheimer's disease
Tecfidera
generics
Mylan
Flag link:
Pages
1
2
3
4
5
6
next ›
last »